N ‐Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis | Zendy

Stec G. Paul | Zendy; Atkinson Arthur J. | Zendy; Nevin Mary Jane | Zendy; Thenot Jean-Paul | Zendy; Ruo Tsuen I. | Zendy; Gibson Thomas P. | Zendy; Ivanovich Peter | Zendy; Greco Francesco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

N ‐Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis

Author(s) -

Stec G. Paul,

Atkinson Arthur J.,

Nevin Mary Jane,

Thenot Jean-Paul,

Ruo Tsuen I.,

Gibson Thomas P.,

Ivanovich Peter,

Greco Francesco

Publication year - 1979

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1002/cpt1979265618

Subject(s) - napa , pharmacokinetics , hemodialysis , dialysis , plasma clearance , urology , renal function , pharmacology , chemistry , medicine , endocrinology , biochemistry

NAPA pharmacokinetics were studied in 6 functionally anephric patients. Distribution and nonrenal elimination of this drug were found to be the same as in individuals with normal renal function but renal clearance was reduced, resulting in a mean elimination t½ of 41.9 hr (6.2 hr in normal subjects). Renal clearance of NAPA correlated well with Cl Cr . Dialysis removed NAPA from both red blood cells and plasma and increased ClTapproximately fourfold. Dialysis itself resulted in a 77% reduction in Cl s that limited the total amount of NAPA removed by this procedure. This reduction in Cl s was sustained for at least 3 hr after dialysis and attenuated rebound in plasma NAPA concentrations.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research